High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study.

gan Jonkhoff, A. R., Plaizier, M. A., Ossenkoppele, G. J., Teule, G. J., Huijgens, P. C.
Cyhoeddwyd 1995

ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination

gan Berge, R., Oudejans, J., Ossenkoppele, G., Pulford, K., Willemze, R., Falini, B., Chott, A., Meijer, C.
Cyhoeddwyd 2000

Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.

gan Noorduyn, L A, de Bruin, P C, van Heerde, P, van de Sandt, M M, Ossenkoppele, G J, Meijer, C J
Cyhoeddwyd 1994

Gallium-67 radiotoxicity in human U937 lymphoma cells.

gan Jonkhoff, A. R., Huijgens, P. C., Versteegh, R. T., van Dieren, E. B., Ossenkoppele, G. J., Martens, H. J., Teule, G. J.
Cyhoeddwyd 1993

Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study

gan van der Poel, M. W. M., Mulder, W. J., Ossenkoppele, G. J., Maartense, E., Hoogendoorn, M., Wijermans, P., Schouten, H. C.
Cyhoeddwyd yn Ann Hematol (2015)

Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.

gan Huijgens, P C, Simoons-Smit, A M, van Loenen, A C, Prooy, E, van Tinteren, H, Ossenkoppele, G J, Jonkhoff, A R
Cyhoeddwyd 1999

Effects of the ACTH(4-9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U937 and U715.

gan Kiburg, B., van de Loosdrecht, A. A., Schweitzer, K. M., Ossenkoppele, G. J., Müller, L. J., Heimans, J. J., Huijgens, P. C.
Cyhoeddwyd 1994

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

gan Laukkanen, S, Grönroos, T, Pölönen, P, Kuusanmäki, H, Mehtonen, J, Cloos, J, Ossenkoppele, G, Gjertsen, B, Øystein, B, Heckman, C, Heinäniemi, M, Kontro, M, Lohi, O
Cyhoeddwyd yn Blood Cancer J (2017)

Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease.

gan Oudejans, J. J., Kummer, J. A., Jiwa, M., van der Valk, P., Ossenkoppele, G. J., Kluin, P. M., Kluin-Nelemans, J. C., Meijer, C. J.
Cyhoeddwyd 1996

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors

gan Thijsen, S F T, Schuurhuis, G J, Oostveen, J W van, Theijsmeijer, A P, van der Hem, K G, Odding, J H, Dräger, A M, Ossenkoppele, G J
Cyhoeddwyd 1999

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the...

gan Russell, Nigel, Douglas, Kenny, Ho, Anthony D., Mohty, Mohamad, Carlson, Kristina, Ossenkoppele, G.J., Milone, Giuseppe, Pareja, Macarena Ortiz, Shaheen, Daniel, Willemsen, Arnold, Whitaker, Nicky, Chabannon, Christian
Cyhoeddwyd 2013

IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival

gan Verhagen, H JMP, de Leeuw, D C, Roemer, M GM, Denkers, F, Pouwels, W, Rutten, A, Celie, P H, Ossenkoppele, G J, Schuurhuis, G J, Smit, L
Cyhoeddwyd yn Cell Death Dis (2014)

A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.

gan Dukers, D F, ten Berge, R L, Oudejans, J J, Pulford, K, Hayes, D, Miseré, J F, Ossenkoppele, G J, Jaspars, L H, Willemze, R, Meijer, C J
Cyhoeddwyd 1999

Hypermethylation of the FANCC and FANCL Promoter Regions in Sporadic Acute Leukaemia

gan Hess, C. J., Ameziane, N., Schuurhuis, G. J., Errami, A., Denkers, F., Kaspers, G. J. L., Cloos, J., Joenje, H., Reinhardt, D., Ossenkoppele, G. J., Zwaan, C. M., Waisfisz, Q.
Cyhoeddwyd yn Cell Oncol (2008)

CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation

gan Stam, A G M, Santegoets, S J A M, Westers, T M, Sombroek, C C, Janssen, J J W M, Tillman, B W, Loosdrecht, A A van de, Pinedo, H M, Curiel, D T, Ossenkoppele, G J, Scheper, R J, de Gruijl, T D
Cyhoeddwyd 2003

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

gan Deenik, W., van der Holt, B., Verhoef, G. E. G., Schattenberg, A. V. M. B., Verdonck, L. F., Daenen, S. M. G. J., Zachée, P., Westveer, P. H. M., Smit, W. M., Wittebol, S., Schouten, H. C., Löwenberg, B., Ossenkoppele, G. J., Cornelissen, J. J.
Cyhoeddwyd yn Ann Hematol (2006)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

gan Hochhaus, A, Rosti, G, Cross, N C P, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, Giles, F J
Cyhoeddwyd yn Leukemia (2016)